Overview

Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
0
Participant gender:
All
Summary
Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Montefiore Medical Center
Collaborators:
M.D. Anderson Cancer Center
The University of Texas Health Science Center, Houston
Treatments:
Fentanyl
Midazolam
Propofol
Rocuronium
Criteria
Inclusion Criteria:

- Adult patients (≥ 18 years old) undergoing elective surgery requiring general
anesthesia

- BMI > 40 kg/m2

- American Society of Anesthesiology (ASA) Physical Status II-III

Exclusion Criteria:

- Chronic hypoxemia (SpO2 <94% on room air or on home oxygen)

- Acute respiratory failure

- Coronary artery disease and/or congestive heart failure

- Moderate-Severe pulmonary hypertension and/or RV dysfunction

- Full stomach (recently eaten)

- Pregnancy

- Chronic pulmonary disease (specifically COPD or interstitial disease, NOT asthma)

- Respiratory tract pathology

- Facial Abnormality

- American Society of Anesthesiology (ASA) Physical Status IV-V